Integrated Wealth Concepts LLC acquired a new stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,140 shares of the company’s stock, valued at approximately $34,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marquette Asset Management LLC bought a new position in Atea Pharmaceuticals in the 1st quarter worth approximately $83,000. CM Wealth Advisors LLC purchased a new position in shares of Atea Pharmaceuticals in the first quarter valued at $64,000. Congress Asset Management Co. MA boosted its stake in Atea Pharmaceuticals by 10.9% in the 1st quarter. Congress Asset Management Co. MA now owns 197,312 shares of the company’s stock worth $661,000 after purchasing an additional 19,400 shares during the period. ETF Managers Group LLC lifted its holdings in shares of Atea Pharmaceuticals by 27.4% in the first quarter. ETF Managers Group LLC now owns 26,460 shares of the company’s stock worth $89,000 after buying an additional 5,695 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Atea Pharmaceuticals by 619.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,716 shares of the company’s stock valued at $79,000 after acquiring an additional 20,421 shares during the period. Institutional investors own 71.33% of the company’s stock.
Atea Pharmaceuticals Trading Down 2.0 %
Atea Pharmaceuticals stock opened at $3.40 on Tuesday. The firm’s 50 day simple moving average is $3.84 and its 200 day simple moving average is $3.78. Atea Pharmaceuticals, Inc. has a 1-year low of $2.94 and a 1-year high of $9.79. The firm has a market capitalization of $283.56 million, a PE ratio of -2.58 and a beta of 0.18.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Featured Stories
- Five stocks we like better than Atea Pharmaceuticals
- How to Invest in Cannabis, Step by Step
- 8 Best Meme Stocks to Buy Now
- Investing In Automotive Stocks
- Is Now The Time To Buy XLF Financial ETF?
- What is the Australian Securities Exchange (ASX)
- Three Ways To Play The Rise In Oil Prices
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
